Lilly Secures Alzheimer's Drug Rights from AlzeCure in Deal Potentially Worth Over $1 Billion
LLY sits 85% above its 52-week low of $623.78.
Summary
Eli Lilly has entered a collaboration and out-licensing agreement with AlzeCure Pharma for global rights to their Alzheimer's project, Alzstatin ACD680. Lilly will pay $10 million upfront, with potential development and commercial milestones that could exceed $1 billion, plus royalties. This strategic partnership expands Lilly's pipeline in the Alzheimer's space with a new gamma-secretase modulator, adding to their existing efforts in this critical disease area.
At the time of this announcement, LLY was trading at $1,155.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: MFN by Modular Finance.